We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Greiner Bio-One

The Preanalytics division develops, manufactures and distributes venous blood collection devices for hospitals, labor... read more Featured Products: More products

Download Mobile App

Greiner Bio-One Highlights Magnetic 3D Cell Culture Technology

By LabMedica International staff writers
Posted on 15 Nov 2023
Print article
Image: Magnetic 3D bioprinting offers new possibilities in high-throughput screening (Photo courtesy of Greiner Bio-One)
Image: Magnetic 3D bioprinting offers new possibilities in high-throughput screening (Photo courtesy of Greiner Bio-One)

Greiner Bio-One (Monroe, NC, USA) is highlighting its magnetic 3D (M3D) cell culture technology which opens up new possibilities in high-throughput screening at MEDICA 2023.

M3D bioprinting combined with cell-repellent surfaces is a superior technology for enabling the miniaturization and speed needed for high-throughput screening. M3D bioprinting enables the uniform generation and ease of manipulation of spheroids/organoids for high-throughput screening by directing magnetized cells to assemble in a controllable size within a shorter culture time. Thus, this technology surpasses the limitations of other high-throughput screening platforms. For improving predictiveness and reducing false positives of high-throughput screening, M3D has shown to be an effective and superior tool to power faster, cheaper, and better results. Moreover, 3D cell culture methodologies are often not easily scalable, meaning that the assumption that one technique used on primary screening is translatable into secondary ones is often inaccurate. A clear benefit for M3D has been its scalability, using the same workflow for high and low throughputs and delivering consistent.

At MEDICA 2023, Greiner Bio-One is also showcasing its safe, effective, and reliable blood collection products for hospitals and clinics. The company’s VACUETTE Safety Products ensure safety and comfort during blood sampling while protecting healthcare staff from blood-borne infections. By using safety products, staff protection is maximized and there is no risk of infection. For the safe transport of samples to the laboratory, Greiner Bio-One offers the VACUETTE – Transport Line range of transport containers of different dimensions in which the Vacuette is transported in an upright position. The transport bags are made of a special isothermal material that maintains a constant temperature of the samples. The transport system protects the samples from heat and mechanical influences. The transport bags also provide storage space for the accompanying medical documentation.

Related Links:
Greiner Bio-One

Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article


Clinical Chemistry

view channel
Image: The new ADLM guidance will help healthcare professionals navigate respiratory virus testing in a post-COVID world (Photo courtesy of 123RF)

New ADLM Guidance Provides Expert Recommendations on Clinical Testing For Respiratory Viral Infections

Respiratory tract infections, predominantly caused by viral pathogens, are a common reason for healthcare visits. Accurate and swift diagnosis of these infections is essential for optimal patient management.... Read more

Molecular Diagnostics

view channel
Image: The HelioLiver Dx test has met the coprimary and secondary study endpoints in the CLiMB trial (Photo courtesy of Helio Genomics)

Blood-Based Test Outperforms Ultrasound in Early Liver Cancer Detection

Patients with liver cirrhosis and chronic hepatitis B are at a higher risk for developing hepatocellular carcinoma (HCC), the most prevalent type of liver cancer. The American Association for the Study... Read more


view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more


view channel
Image: The POC PCR test shortens time for STI test results (Photo courtesy of Visby Medical)

POC STI Test Shortens Time from ED Arrival to Test Results

In a 2024 sexually transmitted infections (STIs) surveillance report by the World Health Organization (WHO), over 2.5 million cases were recorded, alongside a rise in the inappropriate use of antibiotics... Read more


view channel
Image: For 46 years, Roche and Hitachi have collaborated to deliver innovative diagnostic solutions (Photo courtesy of Roche)

Roche and Hitachi High-Tech Extend 46-Year Partnership for Breakthroughs in Diagnostic Testing

Roche (Basel, Switzerland) and Hitachi High-Tech (Tokyo, Japan) have renewed their collaboration agreement, committing to a further 10 years of partnership. This extension brings together their long-standing... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.